News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
598,323 Results
Type
Article (25410)
Company Profile (164)
Press Release (572742)
Multimedia
Podcasts (97)
Webinars (16)
Section
Business (196311)
Career Advice (1140)
Deals (30626)
Drug Delivery (118)
Drug Development (67487)
Employer Resources (88)
FDA (12585)
Job Trends (11455)
News (287321)
Policy (24320)
Tag
2027 BioCapital Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (1358)
Accelerated approval (38)
ADA (50)
Adcomms (25)
Allergies (147)
Alliances (39989)
ALS (146)
Alzheimer's disease (1354)
Antibody-drug conjugate (ADC) (425)
Approvals (13051)
Artificial intelligence (514)
ASCO (329)
Autoimmune disease (271)
Automation (40)
Bankruptcy (316)
Best Places to Work (8973)
BIO (64)
BIOSECURE Act (18)
Biosimilars (180)
Biotechnology (101)
Bladder cancer (176)
Brain cancer (44)
Breast cancer (643)
Cancer (5051)
Cardiovascular disease (421)
Career advice (941)
Career pathing (28)
CAR-T (269)
CDC (43)
Celiac Disease (2)
Cell therapy (726)
Cervical cancer (49)
Clinical research (59919)
Collaboration (1675)
Company closure (1)
Compensation (1451)
Complete response letters (69)
COVID-19 (1544)
CRISPR (85)
C-suite (966)
Cystic fibrosis (118)
Data (7158)
Decentralized trials (2)
Denatured (16)
Depression (139)
Dermatology (82)
Diabetes (549)
Diagnostics (5323)
Digital health (48)
Diversity (8)
Diversity, equity & inclusion (25)
Drug discovery (257)
Drug pricing (197)
Drug shortages (31)
Duchenne muscular dystrophy (229)
Earnings (79980)
Editorial (65)
Employer branding (11)
Employer resources (88)
Events (105306)
Executive appointments (879)
FDA (15710)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (26)
Funding (1266)
Gene editing (180)
Generative AI (49)
Gene therapy (511)
GLP-1 (846)
Government (2633)
Grass and pollen (3)
Guidances (347)
Healthcare (13979)
Hematology (140)
HIV (70)
Huntington's disease (40)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (100)
Immunology and inflammation (252)
Immuno-oncology (93)
Indications (179)
Infectious disease (1835)
Inflammatory bowel disease (172)
Inflation Reduction Act (10)
Influenza (105)
Intellectual property (273)
Interviews (142)
IPO (14264)
IRA (51)
Job creations (2774)
Job search strategy (840)
JPM (40)
Kidney cancer (21)
Labor market (79)
Layoffs (316)
Leadership (32)
Legal (6491)
Liver cancer (64)
Longevity (24)
Lung cancer (706)
Lymphoma (390)
Machine learning (39)
Management (35)
Manufacturing (921)
Marketing (6)
MASH (171)
Medical device (10264)
Medtech (10401)
Mergers & acquisitions (17493)
Metabolic disorders (1382)
mRNA (130)
Multiple sclerosis (147)
NASH (14)
Neurodegenerative disease (324)
Neuropsychiatric disorders (86)
Neuroscience (2572)
Neurotech (1)
NextGen: Class of 2026 (4696)
Non-profit (2897)
Now hiring (46)
Obesity (654)
Opinion (217)
Ovarian cancer (191)
Pain (242)
Pancreatic cancer (280)
Parkinson's disease (275)
Partnered (24)
Patents (549)
Patient recruitment (567)
Peanut (57)
People (50525)
Pharmaceutical (41)
Pharmacy benefit managers (33)
Phase 1 (18485)
Phase 2 (26379)
Phase 3 (19554)
Pipeline (8265)
Policy (286)
Postmarket research (2243)
Preclinical (7948)
Press Release (40)
Prostate cancer (264)
Psychedelics (31)
Radiopharmaceuticals (280)
Rare diseases (906)
Real estate (4219)
Recruiting (36)
Regulatory (19584)
Reports (34)
Research institute (1283)
Resumes & cover letters (193)
Rett syndrome (39)
RNA editing (18)
RSV (76)
Schizophrenia (165)
Series A (212)
Series B (156)
Service/supplier (6)
Sickle cell disease (106)
Special edition (24)
Spinal muscular atrophy (117)
Sponsored (15)
Startups (2662)
Stomach cancer (13)
Supply chain (105)
Tariffs (97)
The Weekly (79)
Vaccines (703)
Venture capital (99)
Weight loss (435)
Women's health (101)
Worklife (11)
Date
Today (56)
Last 7 days (346)
Last 30 days (1463)
Last 365 days (24622)
2026 (13822)
2025 (24587)
2024 (28606)
2023 (32440)
2022 (42374)
2021 (45415)
2020 (42471)
2019 (33571)
2018 (25483)
2017 (24726)
2016 (24177)
2015 (30120)
2014 (25849)
2013 (21725)
2012 (23957)
2011 (24487)
2010 (23834)
Location
Africa (498)
Alabama (77)
Alaska (4)
Arizona (328)
Arkansas (13)
Asia (28098)
Australia (3647)
California (12516)
Canada (3413)
China (999)
Colorado (518)
Connecticut (468)
Delaware (351)
Europe (53542)
Florida (1907)
Georgia (404)
Hawaii (2)
Idaho (51)
Illinois (903)
India (85)
Indiana (464)
Iowa (18)
Japan (529)
Kansas (116)
Kentucky (33)
Louisiana (51)
Maine (29)
Maryland (1354)
Massachusetts (8636)
Michigan (331)
Minnesota (611)
Mississippi (5)
Missouri (111)
Montana (21)
Nebraska (17)
Nevada (119)
New Hampshire (67)
New Jersey (3170)
New Mexico (27)
New York (3127)
North Carolina (1479)
North Dakota (7)
Northern California (6267)
Ohio (334)
Oklahoma (19)
Oregon (25)
Pennsylvania (2403)
Puerto Rico (28)
Rhode Island (40)
South America (864)
South Carolina (77)
South Dakota (1)
Southern California (5128)
Tennessee (153)
Texas (2007)
United States (42598)
Utah (372)
Vermont (2)
Virginia (231)
Washington D.C. (61)
Washington State (993)
West Virginia (2)
Wisconsin (98)
Wyoming (1)
598,323 Results for "dainippon sumitomo pharma america inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026
June 2, 2026
·
6 min read
Press Releases
Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia
June 11, 2026
·
5 min read
Press Releases
Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026, Highlighting Investigational Combination Therapy in Relapsed/Refractory Myelofibrosis and New Research Findings in Menin Inhibition in Leukemia
June 15, 2026
·
7 min read
Press Releases
New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH
May 18, 2026
·
10 min read
Press Releases
Sumitomo Biorational Company Names Remy Lyczko As President, AgroSolutions Division
July 9, 2026
·
2 min read
Press Releases
Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting
November 3, 2025
·
9 min read
Press Releases
Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
December 9, 2025
·
14 min read
Press Releases
Sumitomo Biorational Company Marks Official Launch with Inauguration Event
April 8, 2026
·
3 min read
Press Releases
Sumitomo Pharma America Presents New Data on Vibegron at the 2025 American Urological Association Annual Meeting
April 30, 2025
·
7 min read
Deals
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitomo Pharma Oncology, to Combine and Form Sumitomo Pharma America
Sumitomo Pharma Oncology, Inc., a wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sunovion Pharmaceuticals Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023.
April 3, 2023
·
11 min read
1 of 59,833
Next
